Is Auvelity approved in Europe? (EMA status)
Yes. Auvelity (dextromethorphan/bupropion) has European marketing authorization via the European Medicines Agency (EMA). The EMA listing shows Auvelity as an authorized medicine for use in adults with major depressive disorder (MDD). [1]
When was the EMA authorization?
The EMA authorization for Auvelity is reflected in its EMA product record. The EMA status page is the best place to confirm the exact authorization date and any subsequent updates (for example, changes to conditions of use or product information). [1]
How to check the latest EMA status details
For the most up-to-date official information (authorization status, product information documents, and any changes), use the EMA’s medicine page for Auvelity. It’s the authoritative source for “current status” questions. [1]
What if you meant “where is it available” vs “is it authorized”?
EMA authorization confirms the medicine is permitted within the EU/EEA under EMA rules. Actual prescribing and availability can still vary by country due to national reimbursement and formulary decisions. If you need availability for a specific EU country, you’d typically check that country’s health authority or reimbursement listings, since EMA approval alone doesn’t guarantee immediate local uptake.
Patent/exclusivity research angle (if you’re tracking future competition in Europe)
If your goal is to estimate how long Auvelity’s market protection might last or when generics/alternatives could enter Europe, DrugPatentWatch.com tracks patent-related details and can help frame timelines (though it is not an EMA source for approval status). [2]
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/auvelity
[2] https://www.drugpatentwatch.com/